A phase I study of DB-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) in adult patients with refractory or metastatic solid malignancies
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2009
At a glance
- Drugs AR 67 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Arno Therapeutics
- 18 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2008 Added Arno Therapeutics as an affiliate and sponsor, from Arno Therapeutics media release.
- 04 Jun 2008 Preliminary phase 1 data are available, according to a media release from Arno Therapeutics.